Navidea Biopharmaceuticals to Hold Investor Update Call

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced that the Company will hold an audio webcast conference call on Wednesday, September 7, 2016 at 8:30 a.m. ET to discuss today’s announcement regarding the Letter of Intent for the sale of Lymphoseek in North America to Cardinal Health, Inc.

Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event.

    
      
        
          Event:
        
        
           
        
        
          Navidea Biopharmaceuticals Investor Update Call
        
      
      
        
          Date/Time:
        
        
        
        
          September 7, 2016; 8:30 a.m. ET
        
      
      
        
          Webcast Link:
        
        
        
        
          

http://edge.media-server.com/m/p/m5tcon2v/lan/en

        
      
      
        
          Dial-in Number – US:
        
        
        
        
          [phone]
        
      
      
        
          Dial in Number – Int’l:
        
        
        
        
          [phone]
        
      
      
        
          Conference ID Number:
        
        
        
        
          77978152
        
      
      
        
          Replay:
        
        
        
        
          

A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com for 30 days.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. The development activities of the Manocept immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160906006457/en/

Navidea BiopharmaceuticalsInvestors & MediaSharon Correia, 978-655-2686Senior Director, Corporate Communications